Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran in Late-Breaking Oral Presentation at EAACI 2026
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran as a One-Time Treatment for Hereditary Angioedema
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran ; Hereditary Angioedema Patient-Focused Research at AAAAI 2026
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
LaFleur Minerals Acquires Additional Mineral Claims to Expand Its McKenzie East Gold Project in Quebec's Val-d'Or Mining District
Metalsource Mining Intersects 434 g/t AgEq Over 10.64 Metres at Silver Hill, Including 2.1kg/t AgEq, While Continuing to Expand Mineralization Along Strike and at Depth
Fathom Announces Assays from Metasedimentary Hosted Nickel-Copper-Cobalt Mineralization at the Gochager Lake Project
Terra Clean Energy Corp. Files NI 43-101 Technical Report For the Marysvale Uranium Mines Project, Utah
CHARBONE decroche un contrat d'approvisionnement en hydrogene a long terme avec Hone Inc. pour soutenir les solutions energetiques propres pour l'industrie du divertissement
